Evidence map›Paper›PMID 29606113›Full record

ArticleBMC complementary and alternative medicine2018

MD-1, a poly herbal formulation indicated in diabetes mellitus ameliorates glucose uptake and inhibits adipogenesis - an in vitro study.

Srivani Telapolu, Mangathayaru Kalachavedu, Alan Mathew Punnoose, Dwarakanath Bilikere

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Heliyon · 2022
    Article
  5. Article
  6. Inhibitory evaluation ofJournal of enzyme inhibition and medicinal chemistry · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Srivani TelapoluSRU Center for Indian Systems of Medicine - Quality Assurance and Standardization, Central Research Facility, Sri Ramachandra University, Porur, Chennai, India. srivanipharmacy@gmail.com.
Mangathayaru KalachaveduFaculty of Pharmacy, Sri Ramachandra University, Porur, Chennai, India. manga.kv@sriramachandra.edu.in.
Alan Mathew PunnooseCentre for Regenerative Medicine and Stem Cell Research, Central Research Facility, Sri Ramachandra University, Porur, Chennai, India.
Dwarakanath BilikereSRU Center for Indian Systems of Medicine - Quality Assurance and Standardization, Central Research Facility, Sri Ramachandra University, Porur, Chennai, India.
Sri Ramachandra Institute of Higher Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 Diabetes (T2D) is a polygenic disease requiring a multipronged therapeutic approach. In the current scenario, the use of polyherbals is increasing among the diabetics. MD-1, a poly herbal formulation is constituted as a mixture of six popular anti diabetic herbs, used in the management of Diabetes mellitus (DM). The physicochemical, biochemical and in vitro efficacy studies have been carried out to ascertain the possible mechanisms underlying the anti-diabetic action of MD-1.

methodsMD-1 was evaluated for residual toxins as per Ayurvedic Pharmacoepia of India (API) procedures. The hydro alcoholic extract of the formulation (HAEF) was evaluated for anti oxidant activity against 2, 2-diphenyl-1-picrylhydrazil (DPPH) and nitric oxide radicals in vitro. The effect of HAEF on carbohydrate digestive enzymes α-glucosidase and α-amylase was studied using biochemical assays. HAEF was studied for its glucose lowering potential in L6 myotubes and 3T3L1 preadipocytes, using 2-deoxy-D-[1-

resultsResidual toxins present within the API limits and HAEF demonstrated strong antioxidant potential and significantly inhibited the α-glucosidase (IC

conclusionPhysicochemical parameters established in the study may serve as reference standards in regular quality control. Absence of residual toxins underpins the safety. The enhanced glucose uptake and favorable modulation of insulin sensitivity through a plausible weak PPARγ agonism is similar to the distinct PPARγ activation pattern of several reported natural compound agonists. The differential binding modes of such dynamic combinatorial ligands within the formulation unlike synthetic ligands like thiozolidinediones (TZD) can be linked to the safe mitigation of diabetic complications by MD-1.

Indexed as

3T3-L1 CellsAdipocytesAdipogenesisAnimalsDiabetes Mellitus, Type 2GlucoseGlucose Transporter Type 4MicePlant ExtractsPPAR gammaGlucoseGlucose Transporter Type 4Plant ExtractsPPAR gammaAdipogenesisDiabetes mellitusGlucose transporter 4Glucose uptakePeroxisome proliferator activated receptor gammaPoly herbal formulationStandardization

Identifiers

PMID29606113
PMCPMC5879540
OpenAlexW2801563001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.